Join to access to all OVN content. Join for Free
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
Voices of Oncology Cancer cures Oncology Voice Network Kirk V. Shepard Ramin Farhood Forbes Books Cancer treatment innovation Oncology collaboration Patient engagement in oncology Precision medicine cancer

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures


Share This Article


Summary

  • Voices of Oncology: Fostering a Collaborative Community of Experts to Accelerate Cancer Cures is a book by Kirk V. Shepard, M.D., and Ramin Farhood, PharmD, M.B.A., featuring insights from 33 contributors in the oncology field. It is available on platforms like Amazon and Barnes & Noble.
  • The book presents a forward-looking vision for cancer treatment, emphasizing collaboration among pharmaceutical executives, researchers, patient advocates, and innovation partners.
  • The authors highlight how oncology is being transformed by cultural, technological, and patient engagement changes alongside scientific innovation.
  • Key topics include precision medicine, digital therapeutics, health equity, and the use of real-world data in oncology.
  • The launch of the Oncology Voice Network (OVN) is announced, aiming to connect experts and accelerate progress in cancer care.
  • Drs. Shepard and Farhood emphasize breaking down silos in oncology drug development to foster cross-functional collaboration and speed up cancer treatment advancements.
  • The book is a call to action for unity and innovation as pivotal elements in curing cancer.
  • Dr. Kirk Shepard and Dr. Ramin Farhood bring extensive experience in pharma and medical strategies, respectively, contributing to groundbreaking projects and initiatives.
  • Published by Forbes Books, the book aligns with Forbes' mission of promoting success through innovation and entrepreneurial thinking.

NEW YORK (September 9, 2025)—Voices of Oncology: Fostering a Collaborative Community of Experts to Accelerate Cancer Cures by Kirk V. Shepard, M.D., and Ramin Farhood, PharmD, M.B.A., brings together the insights of 33 distinguished contributors from across the oncology landscape. The book is now available on Amazon and at major booksellers. The book is published with Forbes Books, the exclusive business book publishing imprint of Forbes.

Voices of Oncology offers a bold vision fo r the future of cancer treatment. Through candid interviews and insightful commentary, these voices share real-world experiences, challenges, and solutions—spanning pharmaceutical executives, academic researchers, patient advocates, and innovation partners. With this project, Drs. Shepard and Farhood capture the vital interplay among these diverse perspectives.

The book highlights how oncology is no longer solely driven by scientific innovation, but by seismic shifts in culture, technology, and patient engagement. From precision medicine and digital therapeutics to health equity and real-world data, the contributors outline the structural and cultural changes reshaping oncology today.

This work also marks the launch of the Oncology Voice Network (OVN), a new online community at OncologyVoiceNetwork.com designed to amplify voices, connect experts, and accelerate progress in cancer care.

Voices of Oncology and the Oncology Voice Network (OVN) together take a bold step toward breaking down barriers that isolate partners within the oncology drug development process,” Dr. Farhood said. “Our mission is simple but powerful: to break silos, encourage cross-functional collaboration, and accelerate the development of lifesaving cancer treatments.”

Voices of Oncology is a rallying cry for those who believe that unity and innovation are the keys to a cure.

This release is posted on behalf of Forbes Books (operated by Advantage Media Group under license).

About the Authors

Dr. Kirk Shepard is a US board-certified oncologist and hematologist with over 30 years of experience in pharma, including leadership at Boehringer Ingelheim, Takeda, Baxter, and Eisai. Currently CMO at PDS Biotechnology, he cofounded the Medical Affairs Professional Society (MAPS) and co-edited Medical Affairs (2024).

Dr. Ramin Farhood is a senior medical executive with over 25 years of experience in patient-centric medical strategies, known for leading successful product launches and building global Medical Affairs teams. Currently SVP at SSI Strategy, he cofounded the Medical Affairs Professional Society (MAPS) and Immunoglobulin National Society (IgNS), cohosts The Emerging Biotech Leader podcast, and lectures at USC.

About Forbes Books

Founded in 2016 in partnership with Advantage Media Group, Forbes Books is the exclusive book publishing imprint of Forbes Media. Forbes Books offers business and thought leaders a way to share their ideas and expertise with the world. Authors are carefully vetted to ensure their stories and insights align with the Forbes mission of driving success through innovation and entrepreneurial thinking. For more information, visit books.forbes.com.

Voices of Oncology book cover; book launch announcement.

Click for Source
Voices of Oncology, Cancer cures, Oncology Voice Network, Kirk V. Shepard, Ramin Farhood, Forbes Books, Cancer treatment innovation, Oncology collaboration, Patient engagement in oncology, Precision medicine cancer

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN